IBOGAiN.SE Forum Index
IBOGAiN.SE
Forumet för diskussioner om ibogain och ibogainbehandlingar.
 
 FAQFAQ   SearchSearch   MemberlistMemberlist   UsergroupsUsergroups 
 RegisterRegister   Log in to check your private messagesLog in to check your private messages   ProfileProfile   Log inLog in 

 IndexIndex   search.php?search_id=newposts&sid=be1a97ec6b89fe0e6583320c3c63bba5View posts since last visit

Ibogainkusinen 18-MC testas i en ny studie

Post new topic   Reply to topic    IBOGAiN.SE Forum Index -> -> Nyheter och länkar
View previous topic :: View next topic  
Author Message
Masque
Administratör


Joined: 14 May 2006
Posts: 468
Topics: 68

PostPosted: Tue 30 Jul, 2013 21:39    Post subject: Ibogainkusinen 18-MC testas i en ny studie Reply with quote

Ibogainkusinen 18-MC (18-methoxycoronaridine) kommer att testat i kliniska försök:

Quote:
SAN CARLOS, CA (January 3, 2013): Savant HWP, Inc. today announced the receipt of a three-year grant
to support the development of 18-MC (18-methoxycoronaridine) as a potential orally active treatment
for drug addiction, obesity and other forms of compulsive behavior. The grant, Award Number
U01DA034986 given by the National Institute on Drug Abuse (NIDA) of the National Institutes of Health
(NIH), provides a total of $6,486,657 to support IND-enabling studies and GMP Scale-Up of 18-MC for
use in clinical trials. Savant expects to begin human clinical safety studies of 18-MC in Brazil in early
2013, where the drug will also be studied as a potential treatment for leishmaniasis, and to begin U.S.
clinical development in addiction in 2014.
“Unlike current treatments for drug addiction and nicotine abuse, 18-MC uniquely targets the central
dopamine “reward” pathway involved in all forms of addictive “pleasure-seeking” behaviors, including
over-eating,” said Stephen L. Hurst, Savant HWP Chairman and Chief Executive Officer. “Years of
preclinical research using a variety of addiction models, by Savant’s scientific founder, Stanley D. Glick,
PhD, MD, Director of the Center for Neuropharmacology and Neuroscience at Albany Medical College,
suggests this compound has the potential to bring a major treatment advance to the fields of addiction
medicine and obesity therapy.”
“18-MC is likely to be the first of a new generation of agents effective against a broad spectrum of
addictions—from hard drugs such as heroin and cocaine, to alcohol, nicotine and even sugary, high -fat
foods, possibly reducing obesity rates,” said Dr. Glick, who has studied the neurobiology of addiction for
40 years. “We’re also hopeful that this drug will provide the additional benefit of relief for a completely
unrelated disorder, leishmaniasis, which creates painful skin lesions as well as damaging internal
organs.”


http://www.savanthwp.com/NIDAFunding.010313.pdf

se även http://www.prnewswire.com/news-releases/savant-hwp-announces-nida-funding-for-pre-clinical-development-of-18-mc-as-potential-treatment-for-addiction-obesity-185528492.html
Back to top
View user's profile Send private message
Display posts from previous:   
Post new topic   Reply to topic    IBOGAiN.SE Forum Index -> -> Nyheter och länkar All times are GMT + 1 Hour
Page 1 of 1

 
Jump to:  
You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot vote in polls in this forum
You cannot attach files in this forum
You cannot download files in this forum


Powered by phpBB © 2001, 2005 phpBB Group